ARCHIVES

The Meeting Worth Lobbying For: A “PRG” For Disease-Specific Review; NCI Plans Six.

This article is from The Cancer Letter archive.

Vol. 26 No. 25 | June 23, 2000

Download PDF Visit The Full Archive

Related Articles

Benefit Of Chemotherapy Depends ER Status

April 28, 2006

Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease

March 29, 2013

Cancer Letter, PR Firm Settle Out Of Court On Copyright Violation

November 27, 1987

Translational Research Needs Coordination, Budget, Advisors Say. Former SWOG Chairman Hoogstraten Publishes Memoir.

June 23, 2006

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013

News Analysis: Filing Will Ignite Complex Litigation Costing Millions, With Uncertain Rewards

March 9, 2012